Damora Therapeutics (DMRA) Preferred Stock Liabilities (2019 - 2026)

Damora Therapeutics (DMRA) has 5 years of Preferred Stock Liabilities data on file, last reported at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Preferred Stock Liabilities fell 1.4% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (down 1.4% YoY), and the FY2025 full-year result was $1.3 million, down 1.4% from the prior year.
• Preferred Stock Liabilities for Q1 2026 stood at $1.3 million, roughly flat from $1.3 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $1.4 million in Q4 2024 and bottomed at $1.3 million in Q2 2025.
• The 3-year median for Preferred Stock Liabilities is $1.3 million (2025), against an average of $1.3 million.
• Peak annual rise in Preferred Stock Liabilities reached 1.4% in 2025, while the deepest fall reached 1.4% in 2025.
• A 3-year view of Preferred Stock Liabilities shows it stood at $1.4 million in 2024, then retreated by 1.4% to $1.3 million in 2025, then changed by 0.0% to $1.3 million in 2026.
• The last three Preferred Stock Liabilities figures came in at $1.3 million (Q1 2026), $1.3 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.

Peer Comparison